HOME ABOUT PRODUCTS R&D INVESTORS MEDIA CAREERS CONTACT US ADIENNE is dedicated to the treatment of rare and severe diseases. ADIENNE is focused on the treatment of various hematological and immunological diseases. Begelomab is ADIENNE’s lead clinical product candidate. ADIENNE’s production facility is the center for manufacturing its product candidates. ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs. ADIENNE aims to develop a range of product candidates for orphan diseases for which existing treatment options are limited, the patient population is small and the clinical needs for therapies is high. Site Services Disclaimer Accessibility Privacy Cookie Policy News Alert Site Map Share this page

PHARMACOVIGILANCE MED-INFO Home About Board of Directors Management Manufacturing Products TEPADINA® R&D Research Areas Antibodies Recombinant Proteins Molecules in Development Begelomab MUBODINA® ADN-LYS ADN-MCL Investors Ownership Structure Corporate Governance IR Contact Media Press Releases News Alert Service Media Contact Careers Contact Us Locations About Board of Directors Management Manufacturing Home About Manufacturing Manufacturing ADIENNE’s own production facility is located in Caponago close to Milan (Italy). It is the group’s center for manufacturing its product candidates for preclinical studies and clinical trials in preparation for regulatory approval and in preparation for commercialization. The facility, its processes, equipment and utilities use single-use disposable technology throughout the entire manufacturing process to control and prevent cross-contamination and hence fully comply with Good Manufacturing Practice (“GMP”)-requirements for manufacturing in a multi-product facility. The facility currently has the capability to produce biotechnological products in small batches for preclinical and clinical development and ADIENNE is planning to expand the manufacturing capabilities on-site. Site Services Disclaimer Accessibility Privacy Cookie Policy News Alert Site Map Share this page